Jump to content

Selected Customer Talks

Here is a sampling of conference presentations featuring Genedata Biologics® and the system's implementation and use at leading biopharmaceutical and biotech companies worldwide.

OmniAb
Presented at PEGS, May 2023, Boston, MA, USA

Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep
Bob Chen, Sr. Director, Systems Engineering, OmniAb Inc.

Bob Chen presented a showcase of discovering common light chain antibodies against a NK cell target. OmniDeep is a suite of in silico tools for antibody therapeutic discovery and optimization. Deep screening and high-throughput expression/characterization were used to seed information on top of NGS data sets. The results demonstrate the power of this approach in corralling diverse OmniAb antibody repertoires and accelerating the development of effective therapeutics.

Boehringer Ingelheim Pharmaceuticals
Presented at PEGS, May 2023, Boston, MA, USA

Keynote Presentation: Best Practices for Successful Digital Transformations
Rachel Kroe-Barrett, Sr. Principal Scientist & Dir Biophysics, Boehringer Ingelheim Pharmaceuticals

Digital Transformation of a more than 130-year-old pharmaceutical company is no small feat. Integration of well-established data infrastructure with modern tools is highly complex. An even greater challenge is changing the mindset and culture of data-generating scientists. In this talk, we will share our journey thus far from the perspective of Biotherapeutics Discovery at Boehringer Ingelheim.

Bristol Myers Squibb
Presented at Bio-IT World, May 2023, Boston, MA, USA

Biologics Digital Ecosystem and AI/ML Ready Data
Bharti Gajera, Assoc Dir IT Business Partner, Bristol Myers Squibb

Quality and consistent biotherapeutics data is needed for biologics candidate selection and AI/ML. The biotherapeutics organization currently has multiple systems of record for management of biotherapeutics screening and assay data and different processes per site. Therefore, it has been very challenging for scientists to compile data packages to make informed decisions for selecting drug candidates, comparing molecules generated by different platforms/groups, and applying AI/ML technology for in silico prediction and drug development. We will show how we are simplifying the biotherapeutics data ecosystem and providing a single data capture experience with clear, consistent workflows across discovery biotherapeutics sites.

 

Novartis
Presented at Bio-IT, May 2022, Boston, MA, USA

NIBR’s Journey to Digitalize Biologics Discovery – Value Chain
Bjoern Hueber, Team Leader, Bioinformatics, Novartis
Drazen Nadoveza, Technical Lead and Senior Principal Software Engineer, Novartis

At Novartis Research, we aim to digitalize our biologics discovery processes and workflows to improve and accelerate decision-making and support the digital transformation of our organization. We aim to achieve this by implementing a state-of-the-art data and workflow platform. This platform consists of a central data management solution integrated with a set of diverse tools and applications ensuring seamless integration into NIBR’s existing IT landscape, supporting the uninterrupted flow of data across the organization, and providing the data layer for data science and AI-based applications.

AstraZeneca
Presented at Bio-IT, May 2022, Boston, MA, USA

Digitalization in Biopharma R&D
David Drake, Ph.D., Program Director & Senior Domain Architect, R&D Information, AstraZeneca

Through embedding digital ways of working, AstraZeneca continues to drive scientific innovation and streamline working practices to deliver life-changing medicines to patients. Digitalization of early drug discovery requires us to leverage our technology platforms, provide frictionless access to data, and expand AI/ML insights to enhance decision-making. This presentation discusses the inherent challenges and enabling activities in building a digital capability that accelerates future drug discovery.

Takeda
Presented at Computational Drug Development for Biologics Summit, September 2021, Boston, MA, USA

Biological Registration — Tackling the Ever Changing New modalities
Monica Wang, Principal Technology Lead, Project and Program Management, Scientific Informatics, Takeda Pharmaceuticals

In silico analysis has proven to be an integrative approach for assessing immunogenicity in the preclinical phase. In this talk, we will present an in vitro validation study that provides predictive insights into the immunogenicity of biotherapeutics and address the remaining challenges to provide better predictive insights to mitigate the clinical immunogenicity risk of biotherapeutics.

Sanofi
Presented at Bio-IT, December 2019, San Diego, CA, USA

Platformization of Multi-Specific Protein Engineering: Learning from High-Throughput Screening Data
Norbert Furtmann, Ph.D., Section Head Data Science & Computational Design, Biologics Research, Sanofi

Our novel, automated, high-throughput engineering platform enables the fast generation of large panels of multi-specific variants (up to 10.000), resulting in large data sets (more than 100.000 data points). Here, we report on our visualization and data analysis workflows to improve the understanding of our complex molecules and guide the engineering process.

Janssen
Presented at Bio-IT, April 2019, Boston, MA, USA

Traceability, Findability, Usability
Ruo Steensma, Ph.D., IT Director, Business Technology Leader, Janssen Research and Development, Johnson & Johnson

Data management solutions for biologics discovery at Janssen follow three principles-Traceability, Findability and Usability. Implementation examples of lab systems ranging from raw experimental data to sample tracking to structured data repositories will be presented. Lessons learned will also be discussed.

Pfizer
Presented at Antibody Engineering, December 9-13, 2019, San Diego, CA, USA

Establishing Early Developability Screens to Enable Human PK Prediction
Laura Lin, Ph.D., Executive Director, BioMedicine Design, Pfizer

The presentation will showcase our strategies for assessing early stage viability to enable the selection of clinical candidates. In particular, it will focus on efforts to establish in vitro assays that can predict clearance and PK in humans, and I will present several examples that demonstrate the impact of such assessments on lead selection and optimisation.

Pfizer
Presented at Bio-IT, April 2019, Boston, MA, USA

Using AI to Identify and Navigate Relationships and Identify Context for Pharma Data
Peter Henstock, Ph.D., Machine learning & AI Technical Lead, Business Technology, Pfizer Inc.

As our pharmaceutical datasets continue to grow, the ability to fully utilise them has become more challenging. A baseline approach is search capability, which is provided in various forms from database-level queries to enterprise-level results. The limitations lie in creating the right queries to find all the relevant information without having to create the perfect queries or sift through thousands of entries. The approach relies on text mining, information retrieval, and network analysis, all behind a common user interface, and is currently being developed for multiple databases.

Merck

Merck
Presented at PEGS, April 2019, Boston, MA, USA

From Screening to Quality: Integrated Systems and Databases for Biologics Discovery
Erin Williams, Associate Lab Head of Quality Control, Merck

We have established a global data and workflow platform at Merck for increasing the efficiency of our antibody discovery, protein production, and quality control processes.  We share examples of how the use of this platform has transformed our daily research work, e.g., in organizing and performing QC of produced proteins, including standard and bispecific antibodies, and how it supports discovery and engineering groups using B-cell cloning workflows and engineering of (SEED) bispecific antibodies.

Celgene

Celgene
Presented at PepTalk, January 2019, San Diego, CA, USA

Implementation of an Integrated Bioprocess Development Workflow Platform
Matthew Schwartz, M.Sc., Senior Scientist, Upstream Process Development, Celgene

Celgene’s strategy for implementation of a workflow platform for streamlining development activities will be presented. The new system acts as a cross-functional data backbone that integrates all bioprocess development workflows from post-discovery through transfer to manufacturing and will lead to a significant increase in Celgene’s operational efficiency and throughput. It has the capability to capture output data automatically (online, at-line and offline) along the process from various laboratory equipment.

Bayer

Bayer
Presented at PEGS Europe, November 2018, Lisbon, Portugal

Optimising Developability—Learning from Experimental Data
Lars Linden, Ph.D., Head, Protein Biochemistry, Biologics-Research, Cell and Protein Science, Bayer AG

This presentation will discuss how to address developability early on in lead discovery and later in lead optimization phase. We will feed in experimental data and machine learning concepts, and bring in examples showcasing predictivity of higher throughput in vitro methods.

Kymab

Kymab
Presented at PEGS Europe, November 2018, Lisbon, Portugal

High Throughput Selection of Human Antibodies with Enhanced Developability Properties
Thomas Gallagher, Senior Bioinformatician, Kymab Ltd.

The successful development of biopharmaceutical drugs requires the timely identification, mitigation and resolution of the many challenges presented by the stringent requirements of biological activity, safety and physio-chemical properties. The Kymouse transgenic mouse platform, an advanced in vivo system for the rapid generation of fully human therapeutic monoclonal antibodies, has been coupled to a high throughput in silico developability assessment platform within Kymab. This platform enables the selection of developable high-quality drug candidates.

F-star

F-star
Presented at PEGS Europe, November 2018, Lisbon, Portugal

Identification of a PD-L1 Binding Fcab: A Potent Inhibitor of Immunosuppressive Signals
Jose Munoz Olaya, Ph.D., Principal Scientist, F-star

Checkpoint inhibitors have been very popular and successful targets in the field of immuno-oncology. Here we describe the isolation of an Fcab, an antibody Fc domain modified to bind to a target, specific to PD-L1. The Fcab exhibits high affinity to human PD-L1 that translates into strong potency in cell-based functional assays. An anti-murine surrogate molecule, with similar potency, also exhibits activity in an MC38 syngeneic tumour model. This activity is improved when the Fcab is paired with Fabs targeting other immune checkpoint regulators.

Aptevo

Aptevo
Presented at Bispecific Antibody Pipeline Congress, August 2018, Washington, DC, USA

Bispecific Platform Designed for Rapid Development and Manufacturing of Novel Protein Therapeutics
Peter Pavlik, Ph.D., Principle Scientist, Aptevo Therapeutics

This talk will cover a comprehensive overview of Aptevo’s next generation ADAPTIRTM platform, highlighting improvements that have led to the development of new ADAPTIRTM candidates with increased stability, superior manufacturability and antibody expression levels, and an extended half-life of up to 12.5 days in rodents.

Pfizer

Pfizer
Presented at Bio-IT, May 2018, Boston, MA, USA

Advanced Workflows for End-to-End Biologics
Peter V. Henstock, Senior Principal Scientist, Business Technology, Pfizer & Yuan Lin, Senior Manager, Biologics Business Partner, Pfizer

Sophisticated LIMS and data analysis systems are critical for the success of develop biotherapeutics drugs due to complex nature of biologics drug discovery and development workflows. Current COTS software is too generic to meet the needs of the diverse workflows found acrossour R&D groups. Using the Genedata Biologics platform as an integrated central data repository, we have developed many tools tailored to our internal workflows to help scientists capture detailed biologics entity and process information, enable entity relationship tracking, and analyze large multivariate data. This talk will highlight some of these tools including our recent extension into the bioprocess development area, and discuss some of the architectural challenges and solutions.

Janssen

Janssen
Presented at PEGS, April 2018, Boston, MA, USA

Integrating Biophysical Analyses Earlier in the Discovery Process to Improve Final Lead Selection
Jennifer F. Nemeth, Ph.D., SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development

Biophysical characterization has a critical role in drug discovery from target identification, to early hit lead screening, to intensive structural characterization at the pre-NME stage. Historically, biophysics has been applied heavily in the late discovery phases as a drug candidate approaches the NME declaration. I will examine what assays are having the greatest impact in our workflows across the discovery space, and where we are looking to make in-roads into new functional areas.

Sanofi

Sanofi
Presented at PepTalk, January 2018, San Diego, CA, USA.

Platformization of Multi-Specific Protein Engineering I: From in silico Design and Bulk Modular Cloning to Automated Deconvolution of Variant Libraries
Joerg Birkenfeld, Ph.D., Section Head, High Throughput Biologics, R&D Biologics Research/Protein Therapeutics, Sanofi-Aventis Deutschland GmbH

The success rate to identify a multi-specific lead molecule with favorable drug-like properties increases with the number of variants tested. We report here the establishment of a novel, automated platform process for the fast generation of large panels of multi-specific variants (up to 10,000). Our high-throughput process integrates emerging cloning technologies with state-of-the-art automation and workflow supporting bioinformatics based on Genedata Biologics Database.

Alexion

Alexion
Presented at PEGS, May 2017, Boston, MA, USA

Alexion’s Protein Production Process and Platforms: Comparison of Expi293 and ExpiCHO Expression Systems
Tadas Panavas, Ph.D., Associate Director, Discovery Research, Alexion Pharmaceuticals, Inc.

This presentation will showcase how Alexion has implemented streamlined processes across multiple sites to automate our engineering and production of enzyme replacement therapeutics (ERTs) as well as single and multi-domain antibodies. The selection of expression system for antibody therapeutics and ERTs will be discussed, and thorough comparison between Expi293 and ExpiCHO will be presented.

Kymab

Kymab
Presented at PEGS Europe, November 2016, Lisbon, Portugal

Advances in Kymab’s Fully Integrated, B-Cell Repertoire Analysis and Hit Selection Capabilities
David Melvin, Ph.D., Director of Informatics, Kymab Limited

Kymab have developed an advanced technology to visualise and deeply explore the Kymouse™ antibody repertoire. We can identify candidate-quality molecules with exceptionally broad diversity and with the quality of fully human antibodies. Our platform allows rapid, detailed and efficient exploration of the B-cell response to immunisation as well as informing and supporting decision making process throughout our discovery program. We will present our work with the Bill and Melinda Gates foundation.

Bayer

Bayer HealthCare
Presented at PEGS Europe, November 2016, Lisbon, Portugal

Development of an Automated Parallel System for Production of High-Quality Lead Candidate Antibodies—Keeping Pace with Researchers' Appetites
Lars Linden, Ph.D., Head, Protein Biochemistry, Bayer HealthCare

In early research, project teams profile multiple antibody candidates in functional and often cell-based assays. Within a growing portfolio, this leads to an increasing resource need for the production of mg amounts of high-quality antibodies. To meet this demand, transient transfection and expression were automated, a novel high-throughput 2-step chromatography system was set up, and an integrated automation concept for sample handling was developed.

Pfizer

Pfizer
Presented at PEGS, April 2016, Boston, MA, USA

Database Systems for Consolidation and Analysis of Biotherapeutic Molecular Assessment Results
Joel Bard, Ph.D., Senior Principal Scientist, Global Biotherapeutic Technologies, Pfizer

Global Biotherapeutic Technologies at Pfizer uses a number of biophysical and biochemical assays to predict the developability of early stage biotherapeutics. Data from these assays is used to remove sequence liabilities before they can cause problems in production. To improve access to this data and allow analysis across multiple projects, we have recently implemented a database to store these results and provided web applications to simplify its deposition and analysis.

Pfizer

Pfizer
Presented at Bio-IT World, April 2016, Boston, MA, USA

From Spreadsheets to a Centralized End-to-End Biologics Repository and Analysis Platform
Peter Henstock, Ph.D., Senior Principal Scientist, Research Business Technologies, Pfizer

The challenge described was the alignment of workflows and centralization of data for 200+ Pfizer scientists in 15 groups located at 7 sites. After an aborted earlier attempt with a develop-as-you-go approach, we decided to implement an infrastructure as the backbone platform and central repository of the biological workflows, complemented by a set of custom and proprietary tools used to capture specific instrumental data, workflows, analyses, and nuances of each group’s unique contributions to the overall biological drug discovery process. This talk will show examples of the ecosystem of tools developed and discuss what we learned in the process.

GSK

GSK
Presented at PepTalk, January 2016, San Diego, CA, USA

Comprehensive System to Manage GSK’s Antibody Discovery Processes
Trevor Wattam, Ph.D., Manager, Biopharm Discovery Group, Biopharm Discovery Group, GlaxoSmithKline

GSK’s large-molecule research programs are based on a unique platform of antibody discovery technologies. To support and integrate the different screening, engineering and production processes, we have implemented a comprehensive R&D workflow system called the GSK’s Antibody Discovery Database (ADD). We will present how the ADD makes GSK’s lead discovery process more efficient, with use cases from GSK’s yeast and phage display as well as hybridoma and humanization processes. We will also present concrete applications showing how the ADD supports the design and engineering of novel lead candidates with improved properties, including domain antibodies (dAbs), fusion proteins, bispecifics and ADCs.

Abbvie

AbbVie
Presented at Antibody Engineering & Therapeutics, December 2014, San Diego, CA, USA

An Informatics Platform for High-throughput Design, Screening and Optimization of Bispecific DVD-Ig Molecules
Diana Bowley, Senior Scientist II, AbbVie Bioresearch Center

DVD-Ig proteins are dual-specific antibodies with great therapeutic potential. To scale up and automate Abbvie's DVD-Ig discovery campaigns, we have developed an informatics platform which supports the design, cloning, expression, and purification of large panels of DVD-Ig candidate molecules. This informatics platform also assesses the selectivity, cross reactivity, epitope binding, and stability. The system will enable the parallel engineering of 1,000s of DVD-Ig molecules via combinatorial design of V-domains, linker positions and lengths, and Fc chains.

GSK

GSK
Presented at PEGS Europe, November 2014, Lisbon, Portugal

GSK’s Antibody Discovery Database (ADD), a Comprehensive System to Manage, Share and Exploit Antibody Discovery Processes and Format Information
Trevor Wattam, Ph.D., Manager, Biopharm Discovery Group, Biopharm Discovery Group, GlaxoSmithKline

GSK has a unique combination of antibody discovery technologies. We will present an overview of a comprehensive R&D data management system referred to as theGSK’s  Antibody Discovery Database (ADD), a comprehensive system  used to manage, share and exploit the large amount of relevant and complex information from all our Antibody discovery processes (yeast display, phage display, hybridoma/humanization) and GSKs biopharm formats, including domain antibodies (dAbs), mAbs and bi-specifics.

Takeda

Takeda
Presented at Bio-IT World, May 2014, Boston, MA, USA

Building the Biomolecules Management Platform
Monica Wang, Ph.D., Lead System Engineer, Project and Program Manager, R&D Systems

Building a comprehensive Biomolecules Management Platform is a very challenging task. We are building an enterprise solution to track individual biomolecules in different drug development workflows and visualize their relationships. This platform will improve user efficiency, data quality, data exchange and collaboration for both research and preclinical development departments.

Abbvie

AbbVie
Presented at Bio-IT World, May 2014, Boston, MA, USA

Implementation and Deployment of a Workflow Management System for AbbVie’s Antibody Engineering Groups
Ankita Bhan, PMP, Scientist Informatics, Scientific Informatics and Automation, AbbVie

In order to address the existing and anticipated needs of Antibody engineering groups across the sites at Abbvie, we need to deploy technology based platforms covering the next gen biologics research. Here, we will focus on the successful management of an implementation and deployment project for Abbvie’s antibody lead discovery group leveraging the solution offered by Genedata Biologics.

Bayer

Bayer HealthCare
Presented at Bio-IT World, May 2014, Boston, MA, USA

Development and Implementation of a Biologics Data Platform
Kai Herrmann, Ph.D., R&D IT Project Manager, BBS-ITS-R&D-HCR-BIO, Bayer Business Services

Biopharmaceuticals are increasingly important in the market for new medicines as they provide many advantages over small molecule-based drugs. The discovery and development of biologics molecules such as monoclonal antibodies and recombinant proteins is a complex and time-consuming exercise, and differs substantially from established small-molecule R&D processes. Hence, totally new IT and data management concepts are required. Here, we report our experience over the last 5 years of developing and implementing an innovative turn-key solution for biologics R&D data management. The goal of the new platform was to increase the number and throughput of large-molecule R&D projects, to establish a shared collaboration platform for data exchange, and to improve the quality of results. We present specific challenges encountered, such as process complexity and diversity, process changes, constant adoption to new discovery technologies, direct instrument and robotics integration, and roll-out and system adoption in a large, globally operating biopharmaceutical organization.

UCB

UCB
Presented at Molecular Medicine Tri Conference, February 2014, San Francisco, CA, USA

Biological Registration Systems at UCB and How They Integrate into the Discovery Workflow
David Lee, Ph.D., Principal Scientist, UCB Pharma

The benefits of informatics-driven data management systems are well known in the small molecule therapeutics arena.Extending these systems to supporting biotherapeutics presents a number of challenges. We present a novel data management system, BioQuest, integrating bespoke and best in class software systems designed to capture and integrate NBE data at UCB. We will focus on registration systems,in particular on the antibody and non-antibody protein registration system based on the Genedata Biologics platform.

MorphoSys

MorphoSys
Presented at SLAS, January 2014, San Diego, CA, USA

YBase—A New Integrated Workflow Platform for High-Throughput Antibody Discovery
Biopharmaceuticals and specifically monoclonal antibodies play an increasingly important role in the market for new medicines. The discovery and development of biopharmaceuticals is a complex and time-consuming exercise. MorphoSys is making this more efficient and robust by standardizing and automating the underlying processes in order to scale-up R&D operations. Here, we present the development and implementation of an innovative turn-key solution called YBase which supports biopharma R&D workflow and data management, developed in collaboration with Genedata.  We present the specific challenges encountered, including process complexity and new technology support. Examples cover processes from antibody library generation and screening to protein engineering, expression, purification, and analytics. YBase was built on the Genedata BiologicsTM platform, utilizing a structured and agile development approach. The resulting YBase platform is a powerful resource that enables a very significant increase in the throughput of R&D projects, setting new standards for therapeutic antibody generation in the biopharma industry.

Abbvie

AbbVie
Presented at PepTalk, January 2014, San Diego, CA, USA

An Antibody Engineering Platform for High-Throughput Candidate Screening, Engineering & Optimization
Lorenzo Benatuil, Ph.D., Senior Scientist,  Biologics, AbbVie Bioresearch Center

High-throughput selection and screening of large antibody libraries need a robust data management and analysis platform able to track sequence evolution and aggregate assay data for hit and lead selection. We will present use cases to highlight the impact of incorporating appropriate bioinformatics tools and information management system on antibody generation by AbbVie’s in vitro display technologies.

Bayer

Bayer HealthCare
Presented at PepTalk, January 2014, San Diego, CA, USA

Data Management and Automation of Protein Production Workflows in Biologics R&D
Christoph Freiberg, Ph.D., Senior Scientist, Cell and Protein Sciences, Bayer HealthCare

Our comprehensive workflow platform supports highly parallelized antibody and tool protein production. It uniquely integrates in silico cloning, construct annotation and molecule registration functionalities, while supporting automated and high-throughput evaluation of expression systems of different scales. The molecule’s historical record is faithfully recorded, from early discovery campaigns to engineering and late-stage development. A single system stores molecule hierarchies and associated key expression, purification and analytics data. We thus glean essential information for improving product quality and optimizing production processes.

Abbvie

AbbVie
Presented at Antibody Engineering & Therapeutics, December 2013, San Diego, CA, USA

Bioinformatics and Data Management During Antibody Affinity Maturation by Yeast Display
Lorenzo Benatuil, Ph.D., Senior Scientist,  Biologics, AbbVie Bioresearch Center

Sequences and data management and analysis during the selection and screening of three ~10^9 antibody libraries during an antibody affinity maturation by yeast display. We will present a new workflow platform that enables a significant increase in throughput in the generation and testing of optimized antibody molecules. Concrete use cases illustrating examples from HT Antibody screening & engineering. Examples will cover yeast / phage / mRNA display, and other Ab discovery technologies.

Bayer

Bayer HealthCare
Presented at PepTalk, January 2013, San Diego, CA, USA

Automating HTP Antibody Engineering and Small Scale Production
Christoph Freiberg, Ph.D., Senior Scientist, Cell and Protein Sciences, Bayer HealthCare

We have implemented an automated HT biologics screening and an automated transient mg-scale antibody production process for the discovery, optimization and production of monoclonal antibody leads. We describe a typical workflow from Fab screening via IgG reformatting to IgG research material production with focus on data management supported by Genedata’s Biologics software solution.

UCB

UCB
Presented at PEGS Europe, November 2012, Lisbon, Portugal

Integrating High-Throughput Biotherapeutic and Protein Reagent Expression
David Lee, Ph.D., Principal Scientist, UCB Pharma

Recent advances in cell line development and automation technologies enable the parallel expression of large numbers of biomolecules. We present a novel data management and workflow support system based on Genedata Biologics which captures production and characterization data for both biotherapeutics and tool proteins. The system is optimized for high-throughput processes, spanning molecular biology, expression, purification, and analytics workflows. We will present use cases with emphasis on antibody expression.

UCB

UCB
Presented at Pharmaceutical IT Congress, September 2012, London, UK

Biological Registration Systems at UCB & How They Integrate into the Discovery Workflow
David Lee, Ph.D., Principal Scientist, UCB Pharma

The number and type of biotherapeutics being developed is increasing year on year. The benefits of informatics driven data management systems are well known in the small molecule therapeutics arena. Extending these systems to supporting biotherapeutics presents a number of challenges. We present a novel data management system, BioQuest,integrating bespoke and best in class software systems designed to capture and integrate NBE data at UCB. We will focus on registration systems, in particular on the antibody and non-antibody protein registration system based on the Genedata Biologics platform.

Bayer

Bayer HealthCare
Presented at PEGS, May 2012, Boston, MA, USA

Implementation of a Fully Automated High-Throughput Antibody Engineering Process
Christoph Freiberg, Ph.D., Senior Scientist, Cell and Protein Sciences, Bayer HealthCare

We have implemented an automated HT-biologics screening process for the discovery and optimization of monoclonal antibody leads. We will describe discovery and optimization of monoclonal antibody leads. We will describe examples of our laboratory workflows from Fab screening to lgG reformatting with focus on data management support using Genedata’s Biologics software platform.

Bayer

Bayer HealthCare
Presented at PEGS, May 2011, Boston, MA, USA

A Novel Integrated Data Management Platform for Biologics R&D
Christoph Freiberg, Ph.D., Senior Scientist, Cell and Protein Sciences, Bayer HealthCare

We have implemented an enterprise-level software solution together with our partner Genedata to comprehensively support biologics R&D activities.  We show how we have integrated all steps from HT biologics screening to cell line development into one workflow.

Learn How Genedata Can Accelerate Your R&D

Request a Demo